| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/JMV.1890300303 |
| P698 | PubMed publication ID | 2341832 |
| P50 | author | Peter Reiss | Q92970863 |
| P2093 | author name string | Goudsmit J | |
| Lange JM | |||
| Dekker J | |||
| Debouck C | |||
| de Wolf F | |||
| de Ronde A | |||
| P2860 | cites work | Numbers of CD4+ cells and the levels of core antigens of and antibodies to the human immunodeficiency virus as predictors of AIDS among seropositive homosexual men. | Q45832913 |
| P433 | issue | 3 | |
| P921 | main subject | antibody | Q79460 |
| HIV/AIDS | Q12199 | ||
| P304 | page(s) | 163-168 | |
| P577 | publication date | 1990-03-01 | |
| P1433 | published in | Journal of Medical Virology | Q15716684 |
| P1476 | title | Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1. | |
| P478 | volume | 30 |
| Q44280840 | A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study. |
| Q92906228 | Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease |
| Q73138904 | Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection |
| Q39810236 | Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients. |
| Q41504250 | Antibody to HIV-1 Tat protein inhibits the replication of virus in culture. |
| Q36083803 | Association between different anti-Tat antibody isotypes and HIV disease progression: data from an African cohort |
| Q43499852 | B-cell epitopes in HIV-1 Tat and Rev proteins colocalize with T-cell epitopes and with functional domains |
| Q27333734 | Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines |
| Q34148683 | Challenges in HIV Vaccine Research for Treatment and Prevention |
| Q40806871 | Characterization of HIV-1 Tat proteins mutated in the transactivation domain for prophylactic and therapeutic application. |
| Q40161550 | Characterization of Nef-CXCR4 interactions important for apoptosis induction |
| Q45628437 | Codon optimization and ubiquitin conjugation of human immunodeficiency virus-1 Tat lead to enhanced cell-mediated immune responses |
| Q37348901 | Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization |
| Q37347813 | Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. |
| Q59511395 | Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine |
| Q84240323 | Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice |
| Q43880475 | Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant |
| Q61641083 | Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag |
| Q36486560 | Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein |
| Q43935121 | HIV-1 Nef protein-induced apoptotic cytolysis of a broad spectrum of uninfected human blood cells independently of CD95(Fas). |
| Q41091310 | HIV-1 Tat protein as a potential AIDS vaccine |
| Q46830857 | HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers |
| Q34556390 | HIV-1 Tat vaccines |
| Q46346144 | HIV-1 Tat-specific IgG antibodies in high-responders target a B-cell epitope in the cysteine-rich domain and block extracellular Tat efficiently |
| Q81034939 | Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy |
| Q33739129 | Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice |
| Q33908773 | Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis |
| Q51998598 | Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. |
| Q45722188 | Mucosal delivery of the human immunodeficiency virus-1 Tat protein in mice elicits systemic neutralizing antibodies, cytotoxic T lymphocytes and mucosal IgA. |
| Q36654750 | Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. |
| Q61641127 | NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS* |
| Q51828622 | Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up. |
| Q33828287 | Short communication: circulating plasma HIV-1 viral protein R in dual HIV-1/tuberculosis infection |
| Q50127638 | Subcutaneous administration CpG-ODNs acts as a potent adjuvant for an HIV-1-tat-based vaccine candidate to elicit cellular immunity in BALB/c mice. |
| Q40484822 | Synthetic peptides as diagnostic tools in virology. |
| Q33864926 | The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study |
| Q35024694 | Transactivation and signaling functions of Tat are not correlated: biological and immunological characterization of HIV-1 subtype-C Tat protein |
| Q45012988 | Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). |
Search more.